S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

UroGen Pharma Stock Forecast, Price & News

+0.14 (+1.68%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
95,456 shs
Average Volume
135,911 shs
Market Capitalization
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

UroGen Pharma logo

About UroGen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.


UroGen Pharma to Present at Upcoming Conferences
January 5, 2022 |  finance.yahoo.com
10 Micro-Cap Stocks to Buy According to Cathie Wood
December 14, 2021 |  finance.yahoo.com
Earnings Preview: UroGen Pharma
November 12, 2021 |  benzinga.com
UroGen Pharma Announces Upcoming 2021 Conferences
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$11.80 million
Book Value
$4.61 per share


Net Income
$-128.48 million
Net Margins
Pretax Margin




Free Float

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.33 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

UroGen Pharma (NASDAQ:URGN) Frequently Asked Questions

Is UroGen Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UroGen Pharma stock.
View analyst ratings for UroGen Pharma
or view top-rated stocks.

How has UroGen Pharma's stock been impacted by Coronavirus?

UroGen Pharma's stock was trading at $23.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, URGN shares have decreased by 64.4% and is now trading at $8.49.
View which stocks have been most impacted by COVID-19

When is UroGen Pharma's next earnings date?

UroGen Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for UroGen Pharma

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.26) by $0.09. The company earned $11.35 million during the quarter, compared to the consensus estimate of $15.90 million. UroGen Pharma had a negative net margin of 283.41% and a negative trailing twelve-month return on equity of 173.25%. During the same period last year, the company earned ($1.31) EPS.
View UroGen Pharma's earnings history

What price target have analysts set for URGN?

1 analysts have issued 1 year target prices for UroGen Pharma's stock. Their forecasts range from $50.00 to $50.00. On average, they expect UroGen Pharma's share price to reach $50.00 in the next year. This suggests a possible upside of 488.9% from the stock's current price.
View analysts' price targets for UroGen Pharma
or view top-rated stocks among Wall Street analysts.

Who are UroGen Pharma's key executives?

UroGen Pharma's management team includes the following people:

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu Biopharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is UroGen Pharma's stock symbol?

UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How do I buy shares of UroGen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UroGen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $8.49.

How many employees does UroGen Pharma have?

UroGen Pharma employs 187 workers across the globe.

What is UroGen Pharma's official website?

The official website for UroGen Pharma is www.urogen.com.

Where are UroGen Pharma's headquarters?

UroGen Pharma is headquartered at 400 Alexander Park, Princeton NJ, 08540.

How can I contact UroGen Pharma?

UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at (646) 768-9780 or via email at [email protected].

This page was last updated on 1/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.